The New York Times features an article highlighting the psychiatric communities move away from talk therapy and its increased reliance on prescription drugs as the sole and primary treatment offered to patients. Of concern, is that the shift to drug therapy seems to be driven by a money motive created by the higher insurance reimbursement rates offered for drug treatment verse those of talk therapy, and not based on the actual efficacy of this type of treatment.
A quote from the article:
“Recent studies suggest that talk therapy may be as good as or better than drugs in the treatment of depression, but fewer than half of depressed patients now get such therapy compared with the vast majority 20 years ago. Insurance company reimbursement rates and policies that discourage talk therapy are part of the reason. A psychiatrist can earn $150 for three 15-minute medication visits compared with $90 for a 45-minute talk therapy session.”
Full Article: Talk Doesn’t Pay, So Psychiatry Turns to Drug Therapy